Global Familial Amyloid Polyneuropathy Therapeutic Market 2025 by Company, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Familial Amyloid Polyneuropathy Therapeutic market size was valued at US$ 1589 million in 2024 and is forecast to a readjusted size of USD 2341 million by 2031 with a CAGR of 5.8% during review period.
Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).
The global familial amyloid polyneuropathy (FAP) therapeutic market refers to the market for treatments and therapies aimed at managing and treating familial amyloid polyneuropathy, also known as transthyretin amyloidosis (ATTR). FAP is a rare, progressive, and potentially fatal genetic disorder that affects the peripheral nerves and can lead to various symptoms and complications.
Here are some key points related to the global FAP therapeutic market:
Market Overview: The market for FAP therapeutics includes pharmaceutical drugs, gene therapies, and other treatment options aimed at managing the symptoms and halting the progression of the disease.
Disease-Modifying Therapies: The development of disease-modifying therapies targeting the underlying cause of FAP is a significant focus in this market. These therapies aim to reduce the buildup of abnormal amyloid proteins in the peripheral nerves, which is a hallmark of FAP.
TTR Stabilizers: TTR (transthyretin) stabilizers are pharmacological agents that aim to stabilize the mutated TTR protein and prevent its misfolding and aggregation. Several TTR stabilizers have been approved or are under investigation for their efficacy in treating FAP.
RNA Interference (RNAi) Therapies: RNAi therapies, such as patisiran and inotersen, work by reducing the production of the TTR protein by interfering with the mRNA responsible for its synthesis. These therapies have shown promise in clinical trials and have been approved for the treatment of FAP in some regions.
Liver Transplantation: In some cases, liver transplantation may be considered as a treatment option for FAP. As the liver produces most of the circulating TTR, replacing the diseased liver with a healthy one can halt the production of mutant TTR and slow down the progression of the disease.
Geographic Considerations: The global FAP therapeutic market is influenced by factors such as regional prevalence, healthcare infrastructure, regulatory environments, and reimbursement policies across different countries and regions.
Ongoing Research and Development: The FAP therapeutic market is dynamic, with ongoing research and development efforts focusing on novel therapies and treatment modalities. This includes gene therapies, small molecule inhibitors, and other approaches aimed at providing effective and targeted treatments for FAP.
This report is a detailed and comprehensive analysis for global Familial Amyloid Polyneuropathy Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Familial Amyloid Polyneuropathy Therapeutic market size and forecasts, in consumption value ($ Million), 2020-2031
Global Familial Amyloid Polyneuropathy Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Familial Amyloid Polyneuropathy Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Familial Amyloid Polyneuropathy Therapeutic market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Familial Amyloid Polyneuropathy Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Familial Amyloid Polyneuropathy Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc, Prothena Corporation, Eidos Therapeutics, FoldRx Pharmaceuticals, Akcea Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Familial Amyloid Polyneuropathy Therapeutic market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Familial Amyloid Polyneuropathy Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Familial Amyloid Polyneuropathy Therapeutic, with revenue, gross margin, and global market share of Familial Amyloid Polyneuropathy Therapeutic from 2020 to 2025.
Chapter 3, the Familial Amyloid Polyneuropathy Therapeutic competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Familial Amyloid Polyneuropathy Therapeutic market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Familial Amyloid Polyneuropathy Therapeutic.
Chapter 13, to describe Familial Amyloid Polyneuropathy Therapeutic research findings and conclusion.
Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).
The global familial amyloid polyneuropathy (FAP) therapeutic market refers to the market for treatments and therapies aimed at managing and treating familial amyloid polyneuropathy, also known as transthyretin amyloidosis (ATTR). FAP is a rare, progressive, and potentially fatal genetic disorder that affects the peripheral nerves and can lead to various symptoms and complications.
Here are some key points related to the global FAP therapeutic market:
Market Overview: The market for FAP therapeutics includes pharmaceutical drugs, gene therapies, and other treatment options aimed at managing the symptoms and halting the progression of the disease.
Disease-Modifying Therapies: The development of disease-modifying therapies targeting the underlying cause of FAP is a significant focus in this market. These therapies aim to reduce the buildup of abnormal amyloid proteins in the peripheral nerves, which is a hallmark of FAP.
TTR Stabilizers: TTR (transthyretin) stabilizers are pharmacological agents that aim to stabilize the mutated TTR protein and prevent its misfolding and aggregation. Several TTR stabilizers have been approved or are under investigation for their efficacy in treating FAP.
RNA Interference (RNAi) Therapies: RNAi therapies, such as patisiran and inotersen, work by reducing the production of the TTR protein by interfering with the mRNA responsible for its synthesis. These therapies have shown promise in clinical trials and have been approved for the treatment of FAP in some regions.
Liver Transplantation: In some cases, liver transplantation may be considered as a treatment option for FAP. As the liver produces most of the circulating TTR, replacing the diseased liver with a healthy one can halt the production of mutant TTR and slow down the progression of the disease.
Geographic Considerations: The global FAP therapeutic market is influenced by factors such as regional prevalence, healthcare infrastructure, regulatory environments, and reimbursement policies across different countries and regions.
Ongoing Research and Development: The FAP therapeutic market is dynamic, with ongoing research and development efforts focusing on novel therapies and treatment modalities. This includes gene therapies, small molecule inhibitors, and other approaches aimed at providing effective and targeted treatments for FAP.
This report is a detailed and comprehensive analysis for global Familial Amyloid Polyneuropathy Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Familial Amyloid Polyneuropathy Therapeutic market size and forecasts, in consumption value ($ Million), 2020-2031
Global Familial Amyloid Polyneuropathy Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Familial Amyloid Polyneuropathy Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Familial Amyloid Polyneuropathy Therapeutic market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Familial Amyloid Polyneuropathy Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Familial Amyloid Polyneuropathy Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc, Prothena Corporation, Eidos Therapeutics, FoldRx Pharmaceuticals, Akcea Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Familial Amyloid Polyneuropathy Therapeutic market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Inotersen
- Tafamidis
- Patisiran
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Pfizer Inc.
- Alnylam Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Corino Therapeutics Inc.
- Proclara Biosciences
- Arcturus Therapeutics Inc
- Prothena Corporation
- Eidos Therapeutics
- FoldRx Pharmaceuticals
- Akcea Therapeutics
- GlaxoSmithKline (GSK)
- Greenovation Biotech GmbH
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Familial Amyloid Polyneuropathy Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Familial Amyloid Polyneuropathy Therapeutic, with revenue, gross margin, and global market share of Familial Amyloid Polyneuropathy Therapeutic from 2020 to 2025.
Chapter 3, the Familial Amyloid Polyneuropathy Therapeutic competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Familial Amyloid Polyneuropathy Therapeutic market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Familial Amyloid Polyneuropathy Therapeutic.
Chapter 13, to describe Familial Amyloid Polyneuropathy Therapeutic research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Familial Amyloid Polyneuropathy Therapeutic by Type
1.3.1 Overview: Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type in 2024
1.3.3 Inotersen
1.3.4 Tafamidis
1.3.5 Patisiran
1.3.6 Others
1.4 Global Familial Amyloid Polyneuropathy Therapeutic Market by Application
1.4.1 Overview: Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.4.5 Others
1.5 Global Familial Amyloid Polyneuropathy Therapeutic Market Size & Forecast
1.6 Global Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast by Region
1.6.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region, (2020-2031)
1.6.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
1.6.4 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
1.6.6 South America Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Pfizer Inc.
2.1.1 Pfizer Inc. Details
2.1.2 Pfizer Inc. Major Business
2.1.3 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.1.4 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Pfizer Inc. Recent Developments and Future Plans
2.2 Alnylam Pharmaceuticals Inc.
2.2.1 Alnylam Pharmaceuticals Inc. Details
2.2.2 Alnylam Pharmaceuticals Inc. Major Business
2.2.3 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.2.4 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Alnylam Pharmaceuticals Inc. Recent Developments and Future Plans
2.3 Ionis Pharmaceuticals Inc.
2.3.1 Ionis Pharmaceuticals Inc. Details
2.3.2 Ionis Pharmaceuticals Inc. Major Business
2.3.3 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.3.4 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Ionis Pharmaceuticals Inc. Recent Developments and Future Plans
2.4 Corino Therapeutics Inc.
2.4.1 Corino Therapeutics Inc. Details
2.4.2 Corino Therapeutics Inc. Major Business
2.4.3 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.4.4 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Corino Therapeutics Inc. Recent Developments and Future Plans
2.5 Proclara Biosciences
2.5.1 Proclara Biosciences Details
2.5.2 Proclara Biosciences Major Business
2.5.3 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.5.4 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Proclara Biosciences Recent Developments and Future Plans
2.6 Arcturus Therapeutics Inc
2.6.1 Arcturus Therapeutics Inc Details
2.6.2 Arcturus Therapeutics Inc Major Business
2.6.3 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.6.4 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Arcturus Therapeutics Inc Recent Developments and Future Plans
2.7 Prothena Corporation
2.7.1 Prothena Corporation Details
2.7.2 Prothena Corporation Major Business
2.7.3 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.7.4 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Prothena Corporation Recent Developments and Future Plans
2.8 Eidos Therapeutics
2.8.1 Eidos Therapeutics Details
2.8.2 Eidos Therapeutics Major Business
2.8.3 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.8.4 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Eidos Therapeutics Recent Developments and Future Plans
2.9 FoldRx Pharmaceuticals
2.9.1 FoldRx Pharmaceuticals Details
2.9.2 FoldRx Pharmaceuticals Major Business
2.9.3 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.9.4 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 FoldRx Pharmaceuticals Recent Developments and Future Plans
2.10 Akcea Therapeutics
2.10.1 Akcea Therapeutics Details
2.10.2 Akcea Therapeutics Major Business
2.10.3 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.10.4 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Akcea Therapeutics Recent Developments and Future Plans
2.11 GlaxoSmithKline (GSK)
2.11.1 GlaxoSmithKline (GSK) Details
2.11.2 GlaxoSmithKline (GSK) Major Business
2.11.3 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.11.4 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 GlaxoSmithKline (GSK) Recent Developments and Future Plans
2.12 Greenovation Biotech GmbH
2.12.1 Greenovation Biotech GmbH Details
2.12.2 Greenovation Biotech GmbH Major Business
2.12.3 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.12.4 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Greenovation Biotech GmbH Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Familial Amyloid Polyneuropathy Therapeutic Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Familial Amyloid Polyneuropathy Therapeutic by Company Revenue
3.2.2 Top 3 Familial Amyloid Polyneuropathy Therapeutic Players Market Share in 2024
3.2.3 Top 6 Familial Amyloid Polyneuropathy Therapeutic Players Market Share in 2024
3.3 Familial Amyloid Polyneuropathy Therapeutic Market: Overall Company Footprint Analysis
3.3.1 Familial Amyloid Polyneuropathy Therapeutic Market: Region Footprint
3.3.2 Familial Amyloid Polyneuropathy Therapeutic Market: Company Product Type Footprint
3.3.3 Familial Amyloid Polyneuropathy Therapeutic Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value and Market Share by Type (2020-2025)
4.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2025)
5.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
6.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2020-2031)
6.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
6.3.1 North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2031)
6.3.2 United States Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
6.3.3 Canada Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
6.3.4 Mexico Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
7.2 Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2031)
7.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
7.3.1 Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2031)
7.3.2 Germany Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7.3.3 France Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7.3.5 Russia Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7.3.6 Italy Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region
8.3.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2020-2031)
8.3.2 China Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.3 Japan Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.4 South Korea Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.5 India Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.7 Australia Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
9.2 South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2031)
9.3 South America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
9.3.1 South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2031)
9.3.2 Brazil Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
9.3.3 Argentina Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
10.3.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2031)
10.3.2 Turkey Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
10.3.4 UAE Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Familial Amyloid Polyneuropathy Therapeutic Market Drivers
11.2 Familial Amyloid Polyneuropathy Therapeutic Market Restraints
11.3 Familial Amyloid Polyneuropathy Therapeutic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Familial Amyloid Polyneuropathy Therapeutic Industry Chain
12.2 Familial Amyloid Polyneuropathy Therapeutic Upstream Analysis
12.3 Familial Amyloid Polyneuropathy Therapeutic Midstream Analysis
12.4 Familial Amyloid Polyneuropathy Therapeutic Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Familial Amyloid Polyneuropathy Therapeutic by Type
1.3.1 Overview: Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type in 2024
1.3.3 Inotersen
1.3.4 Tafamidis
1.3.5 Patisiran
1.3.6 Others
1.4 Global Familial Amyloid Polyneuropathy Therapeutic Market by Application
1.4.1 Overview: Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.4.5 Others
1.5 Global Familial Amyloid Polyneuropathy Therapeutic Market Size & Forecast
1.6 Global Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast by Region
1.6.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region, (2020-2031)
1.6.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
1.6.4 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
1.6.6 South America Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Pfizer Inc.
2.1.1 Pfizer Inc. Details
2.1.2 Pfizer Inc. Major Business
2.1.3 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.1.4 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Pfizer Inc. Recent Developments and Future Plans
2.2 Alnylam Pharmaceuticals Inc.
2.2.1 Alnylam Pharmaceuticals Inc. Details
2.2.2 Alnylam Pharmaceuticals Inc. Major Business
2.2.3 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.2.4 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Alnylam Pharmaceuticals Inc. Recent Developments and Future Plans
2.3 Ionis Pharmaceuticals Inc.
2.3.1 Ionis Pharmaceuticals Inc. Details
2.3.2 Ionis Pharmaceuticals Inc. Major Business
2.3.3 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.3.4 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Ionis Pharmaceuticals Inc. Recent Developments and Future Plans
2.4 Corino Therapeutics Inc.
2.4.1 Corino Therapeutics Inc. Details
2.4.2 Corino Therapeutics Inc. Major Business
2.4.3 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.4.4 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Corino Therapeutics Inc. Recent Developments and Future Plans
2.5 Proclara Biosciences
2.5.1 Proclara Biosciences Details
2.5.2 Proclara Biosciences Major Business
2.5.3 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.5.4 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Proclara Biosciences Recent Developments and Future Plans
2.6 Arcturus Therapeutics Inc
2.6.1 Arcturus Therapeutics Inc Details
2.6.2 Arcturus Therapeutics Inc Major Business
2.6.3 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.6.4 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Arcturus Therapeutics Inc Recent Developments and Future Plans
2.7 Prothena Corporation
2.7.1 Prothena Corporation Details
2.7.2 Prothena Corporation Major Business
2.7.3 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.7.4 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Prothena Corporation Recent Developments and Future Plans
2.8 Eidos Therapeutics
2.8.1 Eidos Therapeutics Details
2.8.2 Eidos Therapeutics Major Business
2.8.3 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.8.4 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Eidos Therapeutics Recent Developments and Future Plans
2.9 FoldRx Pharmaceuticals
2.9.1 FoldRx Pharmaceuticals Details
2.9.2 FoldRx Pharmaceuticals Major Business
2.9.3 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.9.4 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 FoldRx Pharmaceuticals Recent Developments and Future Plans
2.10 Akcea Therapeutics
2.10.1 Akcea Therapeutics Details
2.10.2 Akcea Therapeutics Major Business
2.10.3 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.10.4 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Akcea Therapeutics Recent Developments and Future Plans
2.11 GlaxoSmithKline (GSK)
2.11.1 GlaxoSmithKline (GSK) Details
2.11.2 GlaxoSmithKline (GSK) Major Business
2.11.3 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.11.4 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 GlaxoSmithKline (GSK) Recent Developments and Future Plans
2.12 Greenovation Biotech GmbH
2.12.1 Greenovation Biotech GmbH Details
2.12.2 Greenovation Biotech GmbH Major Business
2.12.3 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
2.12.4 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Greenovation Biotech GmbH Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Familial Amyloid Polyneuropathy Therapeutic Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Familial Amyloid Polyneuropathy Therapeutic by Company Revenue
3.2.2 Top 3 Familial Amyloid Polyneuropathy Therapeutic Players Market Share in 2024
3.2.3 Top 6 Familial Amyloid Polyneuropathy Therapeutic Players Market Share in 2024
3.3 Familial Amyloid Polyneuropathy Therapeutic Market: Overall Company Footprint Analysis
3.3.1 Familial Amyloid Polyneuropathy Therapeutic Market: Region Footprint
3.3.2 Familial Amyloid Polyneuropathy Therapeutic Market: Company Product Type Footprint
3.3.3 Familial Amyloid Polyneuropathy Therapeutic Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value and Market Share by Type (2020-2025)
4.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2025)
5.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
6.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2020-2031)
6.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
6.3.1 North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2031)
6.3.2 United States Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
6.3.3 Canada Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
6.3.4 Mexico Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
7.2 Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2031)
7.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
7.3.1 Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2031)
7.3.2 Germany Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7.3.3 France Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7.3.5 Russia Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
7.3.6 Italy Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region
8.3.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2020-2031)
8.3.2 China Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.3 Japan Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.4 South Korea Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.5 India Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
8.3.7 Australia Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
9.2 South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2031)
9.3 South America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
9.3.1 South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2031)
9.3.2 Brazil Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
9.3.3 Argentina Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
10.3.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2031)
10.3.2 Turkey Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
10.3.4 UAE Familial Amyloid Polyneuropathy Therapeutic Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Familial Amyloid Polyneuropathy Therapeutic Market Drivers
11.2 Familial Amyloid Polyneuropathy Therapeutic Market Restraints
11.3 Familial Amyloid Polyneuropathy Therapeutic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Familial Amyloid Polyneuropathy Therapeutic Industry Chain
12.2 Familial Amyloid Polyneuropathy Therapeutic Upstream Analysis
12.3 Familial Amyloid Polyneuropathy Therapeutic Midstream Analysis
12.4 Familial Amyloid Polyneuropathy Therapeutic Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Pfizer Inc. Company Information, Head Office, and Major Competitors
Table 6. Pfizer Inc. Major Business
Table 7. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 8. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Pfizer Inc. Recent Developments and Future Plans
Table 10. Alnylam Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
Table 11. Alnylam Pharmaceuticals Inc. Major Business
Table 12. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 13. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Alnylam Pharmaceuticals Inc. Recent Developments and Future Plans
Table 15. Ionis Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
Table 16. Ionis Pharmaceuticals Inc. Major Business
Table 17. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 18. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Corino Therapeutics Inc. Company Information, Head Office, and Major Competitors
Table 20. Corino Therapeutics Inc. Major Business
Table 21. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 22. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Corino Therapeutics Inc. Recent Developments and Future Plans
Table 24. Proclara Biosciences Company Information, Head Office, and Major Competitors
Table 25. Proclara Biosciences Major Business
Table 26. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 27. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Proclara Biosciences Recent Developments and Future Plans
Table 29. Arcturus Therapeutics Inc Company Information, Head Office, and Major Competitors
Table 30. Arcturus Therapeutics Inc Major Business
Table 31. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 32. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Arcturus Therapeutics Inc Recent Developments and Future Plans
Table 34. Prothena Corporation Company Information, Head Office, and Major Competitors
Table 35. Prothena Corporation Major Business
Table 36. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 37. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Prothena Corporation Recent Developments and Future Plans
Table 39. Eidos Therapeutics Company Information, Head Office, and Major Competitors
Table 40. Eidos Therapeutics Major Business
Table 41. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 42. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Eidos Therapeutics Recent Developments and Future Plans
Table 44. FoldRx Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 45. FoldRx Pharmaceuticals Major Business
Table 46. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 47. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. FoldRx Pharmaceuticals Recent Developments and Future Plans
Table 49. Akcea Therapeutics Company Information, Head Office, and Major Competitors
Table 50. Akcea Therapeutics Major Business
Table 51. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 52. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Akcea Therapeutics Recent Developments and Future Plans
Table 54. GlaxoSmithKline (GSK) Company Information, Head Office, and Major Competitors
Table 55. GlaxoSmithKline (GSK) Major Business
Table 56. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 57. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. GlaxoSmithKline (GSK) Recent Developments and Future Plans
Table 59. Greenovation Biotech GmbH Company Information, Head Office, and Major Competitors
Table 60. Greenovation Biotech GmbH Major Business
Table 61. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 62. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Greenovation Biotech GmbH Recent Developments and Future Plans
Table 64. Global Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million) by Players (2020-2025)
Table 65. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Players (2020-2025)
Table 66. Breakdown of Familial Amyloid Polyneuropathy Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3)
Table 67. Market Position of Players in Familial Amyloid Polyneuropathy Therapeutic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 68. Head Office of Key Familial Amyloid Polyneuropathy Therapeutic Players
Table 69. Familial Amyloid Polyneuropathy Therapeutic Market: Company Product Type Footprint
Table 70. Familial Amyloid Polyneuropathy Therapeutic Market: Company Product Application Footprint
Table 71. Familial Amyloid Polyneuropathy Therapeutic New Market Entrants and Barriers to Market Entry
Table 72. Familial Amyloid Polyneuropathy Therapeutic Mergers, Acquisition, Agreements, and Collaborations
Table 73. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value (USD Million) by Type (2020-2025)
Table 74. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Share by Type (2020-2025)
Table 75. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Forecast by Type (2026-2031)
Table 76. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025)
Table 77. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Forecast by Application (2026-2031)
Table 78. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 79. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 80. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 81. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 82. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 83. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 84. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 85. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 86. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 87. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 88. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 89. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 90. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 91. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 92. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 93. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 94. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2020-2025) & (USD Million)
Table 95. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2026-2031) & (USD Million)
Table 96. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 97. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 98. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 99. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 100. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 101. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 102. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 103. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 104. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 105. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 106. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 107. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 108. Global Key Players of Familial Amyloid Polyneuropathy Therapeutic Upstream (Raw Materials)
Table 109. Global Familial Amyloid Polyneuropathy Therapeutic Typical Customers
Table 1. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Pfizer Inc. Company Information, Head Office, and Major Competitors
Table 6. Pfizer Inc. Major Business
Table 7. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 8. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Pfizer Inc. Recent Developments and Future Plans
Table 10. Alnylam Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
Table 11. Alnylam Pharmaceuticals Inc. Major Business
Table 12. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 13. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Alnylam Pharmaceuticals Inc. Recent Developments and Future Plans
Table 15. Ionis Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
Table 16. Ionis Pharmaceuticals Inc. Major Business
Table 17. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 18. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Corino Therapeutics Inc. Company Information, Head Office, and Major Competitors
Table 20. Corino Therapeutics Inc. Major Business
Table 21. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 22. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Corino Therapeutics Inc. Recent Developments and Future Plans
Table 24. Proclara Biosciences Company Information, Head Office, and Major Competitors
Table 25. Proclara Biosciences Major Business
Table 26. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 27. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Proclara Biosciences Recent Developments and Future Plans
Table 29. Arcturus Therapeutics Inc Company Information, Head Office, and Major Competitors
Table 30. Arcturus Therapeutics Inc Major Business
Table 31. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 32. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Arcturus Therapeutics Inc Recent Developments and Future Plans
Table 34. Prothena Corporation Company Information, Head Office, and Major Competitors
Table 35. Prothena Corporation Major Business
Table 36. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 37. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Prothena Corporation Recent Developments and Future Plans
Table 39. Eidos Therapeutics Company Information, Head Office, and Major Competitors
Table 40. Eidos Therapeutics Major Business
Table 41. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 42. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Eidos Therapeutics Recent Developments and Future Plans
Table 44. FoldRx Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 45. FoldRx Pharmaceuticals Major Business
Table 46. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 47. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. FoldRx Pharmaceuticals Recent Developments and Future Plans
Table 49. Akcea Therapeutics Company Information, Head Office, and Major Competitors
Table 50. Akcea Therapeutics Major Business
Table 51. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 52. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Akcea Therapeutics Recent Developments and Future Plans
Table 54. GlaxoSmithKline (GSK) Company Information, Head Office, and Major Competitors
Table 55. GlaxoSmithKline (GSK) Major Business
Table 56. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 57. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. GlaxoSmithKline (GSK) Recent Developments and Future Plans
Table 59. Greenovation Biotech GmbH Company Information, Head Office, and Major Competitors
Table 60. Greenovation Biotech GmbH Major Business
Table 61. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product and Solutions
Table 62. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Greenovation Biotech GmbH Recent Developments and Future Plans
Table 64. Global Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million) by Players (2020-2025)
Table 65. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Players (2020-2025)
Table 66. Breakdown of Familial Amyloid Polyneuropathy Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3)
Table 67. Market Position of Players in Familial Amyloid Polyneuropathy Therapeutic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 68. Head Office of Key Familial Amyloid Polyneuropathy Therapeutic Players
Table 69. Familial Amyloid Polyneuropathy Therapeutic Market: Company Product Type Footprint
Table 70. Familial Amyloid Polyneuropathy Therapeutic Market: Company Product Application Footprint
Table 71. Familial Amyloid Polyneuropathy Therapeutic New Market Entrants and Barriers to Market Entry
Table 72. Familial Amyloid Polyneuropathy Therapeutic Mergers, Acquisition, Agreements, and Collaborations
Table 73. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value (USD Million) by Type (2020-2025)
Table 74. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Share by Type (2020-2025)
Table 75. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Forecast by Type (2026-2031)
Table 76. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025)
Table 77. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Forecast by Application (2026-2031)
Table 78. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 79. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 80. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 81. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 82. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 83. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 84. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 85. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 86. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 87. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 88. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 89. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 90. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 91. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 92. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 93. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 94. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2020-2025) & (USD Million)
Table 95. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Region (2026-2031) & (USD Million)
Table 96. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 97. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 98. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 99. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 100. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 101. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 102. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2020-2025) & (USD Million)
Table 103. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type (2026-2031) & (USD Million)
Table 104. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2020-2025) & (USD Million)
Table 105. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application (2026-2031) & (USD Million)
Table 106. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2020-2025) & (USD Million)
Table 107. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Country (2026-2031) & (USD Million)
Table 108. Global Key Players of Familial Amyloid Polyneuropathy Therapeutic Upstream (Raw Materials)
Table 109. Global Familial Amyloid Polyneuropathy Therapeutic Typical Customers
LIST OF FIGURES
Figure 1. Familial Amyloid Polyneuropathy Therapeutic Picture
Figure 2. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type in 2024
Figure 4. Inotersen
Figure 5. Tafamidis
Figure 6. Patisiran
Figure 7. Others
Figure 8. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 9. Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application in 2024
Figure 10. Hospital Pharmacies Picture
Figure 11. Retail Pharmacies Picture
Figure 12. Online Pharmacies Picture
Figure 13. Others Picture
Figure 14. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 15. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 16. Global Market Familial Amyloid Polyneuropathy Therapeutic Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 17. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Region (2020-2031)
Figure 18. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Region in 2024
Figure 19. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 20. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 21. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 22. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 23. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 24. Company Three Recent Developments and Future Plans
Figure 25. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Players in 2024
Figure 26. Familial Amyloid Polyneuropathy Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 27. Market Share of Familial Amyloid Polyneuropathy Therapeutic by Player Revenue in 2024
Figure 28. Top 3 Familial Amyloid Polyneuropathy Therapeutic Players Market Share in 2024
Figure 29. Top 6 Familial Amyloid Polyneuropathy Therapeutic Players Market Share in 2024
Figure 30. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Share by Type (2020-2025)
Figure 31. Global Familial Amyloid Polyneuropathy Therapeutic Market Share Forecast by Type (2026-2031)
Figure 32. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Share by Application (2020-2025)
Figure 33. Global Familial Amyloid Polyneuropathy Therapeutic Market Share Forecast by Application (2026-2031)
Figure 34. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 35. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 36. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 37. United States Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 38. Canada Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 39. Mexico Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 40. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 41. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 42. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 43. Germany Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 44. France Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 45. United Kingdom Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 46. Russia Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 47. Italy Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 48. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 49. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 50. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Region (2020-2031)
Figure 51. China Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 52. Japan Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 53. South Korea Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 54. India Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 55. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 56. Australia Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 57. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 58. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 59. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 60. Brazil Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 61. Argentina Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 62. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 63. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 64. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 65. Turkey Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 66. Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 67. UAE Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 68. Familial Amyloid Polyneuropathy Therapeutic Market Drivers
Figure 69. Familial Amyloid Polyneuropathy Therapeutic Market Restraints
Figure 70. Familial Amyloid Polyneuropathy Therapeutic Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Familial Amyloid Polyneuropathy Therapeutic Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Figure 1. Familial Amyloid Polyneuropathy Therapeutic Picture
Figure 2. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type in 2024
Figure 4. Inotersen
Figure 5. Tafamidis
Figure 6. Patisiran
Figure 7. Others
Figure 8. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 9. Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application in 2024
Figure 10. Hospital Pharmacies Picture
Figure 11. Retail Pharmacies Picture
Figure 12. Online Pharmacies Picture
Figure 13. Others Picture
Figure 14. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 15. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 16. Global Market Familial Amyloid Polyneuropathy Therapeutic Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 17. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Region (2020-2031)
Figure 18. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Region in 2024
Figure 19. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 20. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 21. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 22. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 23. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 24. Company Three Recent Developments and Future Plans
Figure 25. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Players in 2024
Figure 26. Familial Amyloid Polyneuropathy Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 27. Market Share of Familial Amyloid Polyneuropathy Therapeutic by Player Revenue in 2024
Figure 28. Top 3 Familial Amyloid Polyneuropathy Therapeutic Players Market Share in 2024
Figure 29. Top 6 Familial Amyloid Polyneuropathy Therapeutic Players Market Share in 2024
Figure 30. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Share by Type (2020-2025)
Figure 31. Global Familial Amyloid Polyneuropathy Therapeutic Market Share Forecast by Type (2026-2031)
Figure 32. Global Familial Amyloid Polyneuropathy Therapeutic Consumption Value Share by Application (2020-2025)
Figure 33. Global Familial Amyloid Polyneuropathy Therapeutic Market Share Forecast by Application (2026-2031)
Figure 34. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 35. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 36. North America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 37. United States Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 38. Canada Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 39. Mexico Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 40. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 41. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 42. Europe Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 43. Germany Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 44. France Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 45. United Kingdom Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 46. Russia Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 47. Italy Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 48. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 49. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 50. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Region (2020-2031)
Figure 51. China Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 52. Japan Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 53. South Korea Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 54. India Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 55. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 56. Australia Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 57. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 58. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 59. South America Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 60. Brazil Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 61. Argentina Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 62. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Type (2020-2031)
Figure 63. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Application (2020-2031)
Figure 64. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Value Market Share by Country (2020-2031)
Figure 65. Turkey Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 66. Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 67. UAE Familial Amyloid Polyneuropathy Therapeutic Consumption Value (2020-2031) & (USD Million)
Figure 68. Familial Amyloid Polyneuropathy Therapeutic Market Drivers
Figure 69. Familial Amyloid Polyneuropathy Therapeutic Market Restraints
Figure 70. Familial Amyloid Polyneuropathy Therapeutic Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Familial Amyloid Polyneuropathy Therapeutic Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
